ZUG, Switzerland, February 9, 2016 /PRNewswire/ --
LifeWatch AG (SIX Swiss Exchange: LIFE), a leading developer and
provider of medical solutions and remote diagnostic monitoring
services in the digital health market, is pleased to announce that
it has received FDA clearance for its continuous Vital Signs
Monitoring Service.
The wireless, patch-based vital signs monitoring system makes
vital signs monitoring faster, easier and more convenient for both,
patients and medical staff. It will allow for early detection of
vital sign changes thereby enabling faster interventions as well as
increased nursing efficiency and higher patient satisfaction.
The Vital Signs Patch is an easy-to-use cable-free sensor worn
on a patient's upper chest. It is intended to be used on adult
patients in a clinical environment for the continuous, non-invasive
monitoring of ECG, heart rate, respiration rate, surface
temperature, arterial blood oxygen saturation and body position. It
will be available in two versions (with and without ECG) and is
connected with an easy-to-use wireless supporting system, which
provides medical information and alerts remotely to medical staff.
Although the system will initially be used in a medical facility
(hospital, nursing home, etc.), the even larger ambulatory market
should follow once the technology has been proven in the clinical
environment.
Dr. Stephan Rietiker, CEO of
LifeWatch, stated: "This clearance represents another significant
technological breakthrough for LifeWatch and further strengthens
our position as an innovational leader in digital health. I am
highly excited at the tremendous market potential for the
easy-to-use Vital Signs Patch, both in the clinical and ambulatory
settings worldwide. Furthermore, the cost benefits will allow vital
signs monitoring to be utilized for a much broader patient
population. However, providing service in a clinical environment is
a new market for LifeWatch and will therefore require both time and
additional resources in order to ensure a successful market
launch."
About LifeWatch AG:
LifeWatch AG, headquartered in Zug and listed on SIX Swiss
Exchange (LIFE),
Switzerland, is a leading
healthcare technology and solution company, specializing in
advanced digital health systems and wireless remote diagnostic
patient monitoring services. LifeWatch's services provide
physicians with critical information to determine appropriate
treatment and thereby improve patient outcomes. LifeWatch AG has
operative subsidiaries in the United
States, in Switzerland and
in Israel, and is the parent
company of LifeWatch Services Inc., and LifeWatch Technologies,
Ltd. LifeWatch Services, Inc. is a leading U.S.-based provider of
cardiac monitoring services and home sleep testing of Obstructive
Sleep Apnea (OSA). LifeWatch Technologies Ltd., based in
Israel, is a leading developer and
manufacturer of telemedicine products. For additional information,
please visit http://www.lifewatch.com.
Sign up for customized e-mail alerts and documentation
requests at
http://www.irlifewatch.com/alert-service.aspx
This press release includes forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding future results
of operations and financial position, the business strategy, and
plans and objectives for future operations, are forward-looking
statements. The words "believe," "may," "will," "estimate,"
"continue," "anticipate," "intend," "expect" and similar
expressions are intended to identify forward-looking statements.
LifeWatch AG has based these forward-looking statements largely on
current expectations and projections about future events and
financial trends that it believes may affect the financial
condition, results of operations, business strategy, short-term and
long-term business operations and objectives, and financial needs.
These forward-looking statements are subject to a number of risks,
uncertainties and assumptions. In light of these risks,
uncertainties and assumptions, the forward-looking events and
circumstances described may not occur and actual results could
differ materially and adversely from those anticipated or implied
in the forward-looking statements. All forward-looking statements
are based only on data available to LifeWatch AG at the time of the
issue of this press release. LifeWatch AG does not undertake any
obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or
otherwise.
THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE
DISTRIBUTED TO UNITED STATES
PERSONS OR PUBLICATIONS WITH A GENERAL
CIRCULATION IN THE UNITED STATES.
THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF
LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES, OR AN INVITATION TO
SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH AG OR ITS
SUBSIDIARIES IN THE UNITED STATES.
IN ADDITION, THE SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES
HAVE NOT BEEN REGISTERED UNDER THE UNITED
STATES
SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN
THE UNITED STATES OR TO U.S.
PERSONS ABSENT FROM REGISTRATION UNDER OR AN APPLICABLE
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY PUBLIC
OFFERING OF SECURITIES TO BE MADE IN THE
UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY
BE OBTAINED FROM LIFEWATCH AG OR ITS SUBSIDIARIES, AS APPLICABLE,
AND WILL CONTAIN DETAILED INFORMATION ABOUT THE ISSUER AND ITS
MANAGEMENT AS WELL AS FINANCIAL STATEMENTS OF THE ISSUER.
For further questions:
LifeWatch AG
c/o Dynamics Group, Philippe Blangey / Doris Rudischhauser
Phone: +41-43-268-32-35 / +41-79-410-81-88
E-mail: investor-relations@lifewatch.com
SOURCE LifeWatch AG